Cargando…
PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy
INTRODUCTION: Xerostomia is a well-known complication after iodine-131 ((131)I) therapy for thyroid carcinoma. It is currently insufficiently understood how the dose and biodistribution of (131)I relates to salivary gland toxicity, and whether this is consistent for all salivary glands within a sing...
Autores principales: | Mohan, Vineet, Vogel, Wouter V., Valk, Gerlof D., de Boer, Jan P., Lam, Marnix G. E. H., de Keizer, Bart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493237/ https://www.ncbi.nlm.nih.gov/pubmed/32619138 http://dx.doi.org/10.1177/1536012120934992 |
Ejemplares similares
-
(68)Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with (177)Lu-PSMA-617
por: de Vries, Lisa H., et al.
Publicado: (2020) -
Impact of external cooling with icepacks on (68)Ga-PSMA uptake in salivary glands
por: van Kalmthout, Ludwike W. M., et al.
Publicado: (2018) -
The effect of eating on the uptake of PSMA ligands in the salivary glands
por: Mohan, V., et al.
Publicado: (2021) -
First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
por: Klein Nulent, Thomas J. W., et al.
Publicado: (2021) -
Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine
por: Mohan, V., et al.
Publicado: (2021)